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Abstract
The present study examined plasma lipid profiles in thirty patients suffered from acute viral hepatitis. Patients’
blood samples were collected at both the debut and recovery of diseases. Thirty sex and age matched normal
subjects were included as controls. Plasma total triglycerides (TG), total cholesterol, high density lipoprotein choles-
terol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein AI (ApoAI), apolipoprotein B (ApoB), lipo-
protein (a) (Lp(a)), blood coagulation status including prothrombin complex activity and activated partial
tromboplastin time (APTT), and hepatic functions were determined by the automatic biochemical analytical instru-
ment. It demonstrated that plasma levels of total cholesterol, HDL-C and apoAI were significantly lower in the
patients at the acute phase of hepatitis than those in normal subjects, whereas plasma levels of TG and LDL-C
were obviously higher in the patients than in normal subjects (P < 0.05). Moreover, we demonstrated that patients’
plasma levels of total cholesterol, LDL-C, HDL-C and apoAI were lower at the active phase of the diseases than at
the recovering phase, which indicating that acute liver damage could significant influence lipid metabolism in vivo.
No pathological changes of blood coagulation status occurred in these patients during the study as all selected
patients had moderate hepatitis. It may conclude that examinations of plasma lipid profile could be considered as
a clinical index to reflect liver damage in the active phase of hepatitis.
Introduction
Liver is the most important organ for the metabolism of
lipids, lipoproteins and apolipoproteins. Under normal
circumstances, most plasma endogenous lipids and lipo-
proteins are synthesized in the liver and then are
secreted into the blood circulation [1,2]. And plasma
lipoproteins are also mainly catabolism by the liver to
maintain the relative balance of lipid and lipoprotein
metabolism in vivo [3]. It has been well documented
that chronic liver dysfunction might interfere lipid meta-
bolism in vivo and could change plasma lipid and lipo-
protein patterns [4]. Acute hepatitis may be referred to
an inflammatory process of the liver lasting less than six
months. In China, the most common etiology of acute
hepatitis is viral infection, in which hepatitis A and
hepatitis E are the most common causes. In clinical, the
courses of acute hepatitis may vary widely from mild
symptom that does not require treatment to the fulmi-
nant hepatic failure that needs emergency liver trans-
plantation. Acute viral hepatitis is more likely to be
asymptomatic in younger people. In addition, acute
hepatitis may occur less commonly with infections such
as Epstein-Barr virus, cytomegalovirus, adenovirus,
herpes simplex and Coxsackie virus or with other non-
infectious reasons. It has been demonstrated that in the
acute and/or chronic liver diseases, hepatic function
could be impaired and the circulating lipids and lipopro-
teins are not only present in abnormal amounts but they
frequently also have abnormal composition including
electrophoretic mobility and appearance [4]. Previous
studies pay more emphasis on changes of lipid metabo-
lisms under chronic hepatitis and cirrhosis with or with-
out hepatocellular carcinoma [5-7]. In the present study
we followed plasma lipid and lipoprotein patterns of
patients suffered from acute hepatitis to further explore
the changes of lipid and lipoprotein profiles of the
patients.
Materials and methods
Patients and normal subjects
Thirty cases of acute hepatitis patients who were
admitted to the hospital’s inpatients were subjected in
the present study, 21 males and 9 females, aged from 19
to 81 years old. All patients had moderate hepatitis.
Clinical diagnosis was applied according to the diagnos-
tic criteria of “Viral Hepatitis Prevention Program” of
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tious Diseases [8]. The characterization of the patients is
listed in the table 1. Data concerning virus antigen and
antibody, and viral loads in blood is shown in the Table
2. And there was no any patient with HIV positive in
the present study. There was no patient received anti-
viral drug therapy, blood transfusions or plasmapheresis.
Duration of hospitalization all patients were given liver
protective therapy and advised to have proper rest and
go on rational diet. Some patients were given traditional
Chinese medicine to improve liver function. In the pre-
sent study there was no patient underwent liver biopsy.
A n du pt on o wt h e r ew a sn op a t i e n tw a sf o u n dt o
develop chronic active hepatitis. Thirty healthy subjects,
16 males and 14 females, aged from 20 to 63 years old,
were included as controls. All normal subjects were con-
firmed by the negative results of serum biochemical
tests, virus tests and B-type ultrasonic inspection to
exclude hepatitis or other chronic liver diseases and
metabolic diseases. Fasting blood samples were obtained
and preserved at -70°C before further examination. The
present study was approved by the local Ethics
Committee.
Laboratory analyses
Blood was collected from all subjects under standardised
conditions after overnight fasting. Triglycerides (TG)
and total cholesterol were determined by the endpoint
detection (GPO-PAP Method, CHO-PAP Method).
ApoA, apoB as well as Lp(a) were determined by the
immunological turbidimetric method. All laboratory
parameters were directly determined on an automatic
biochemical analyzer (Olympus AU2700, Japan).
Patients’ coagulation status including prothrombin com-
plex activity and activated partial tromboplastin time
(APTT), were determined as a routine test and patients’
coagulation status was at normal ranges.
Statistical analysis
Statistical analysis was performed with the GraphPad
Prism version 5. Data are expressed as means ± SD. Dif-
ferences between patients and healthy subjects were
compared by the non-paired t-test. Lipid profiles in
patients under different diseases phases were analyzed
by the one-way ANOVA followed by the paired t-test. A
p value less than 0.05 (P < 0.05) was considered as
significant.
Results
As shown in figure 1, serum levels of total cholesterol,
HDL-C and apoAI were significantly lower in the acute
hepatitis patients compared to the normal subjects,
whereas serum levels of TG and LDL-C were obviously
higher in the patients than in normal subjects (P <
0.05). Moreover, we demonstrated that patients’ serum
levels of total cholesterol, LDL-cholesterol, HDL-choles-
t e r o la n da p o A Iw e r el o w e ra tt h ea c t i v ep h a s eo ft h e
diseases than at the recovering phase (Figure 2). There
is no statistical significant correlation between the
plasma viraemia and the changes of lipid profiles (data
not shown).
Discussion
Liver is one of the most important organs for the meta-
bolism of plasma apolipoproteins, endogenous lipids and
lipoproteins. Most plasma apolipoproteins, endogenous
lipids and lipoproteins are synthesized by the liver [1,2],
which depends on the integrity of cellular functions of
liver [2,3]. As in blood circulation lipids do not dissolve
in plasma, they need in combination with different apo-
lipoproteins to form lipoproteins that may transfer
endogenous or exogenous lipids to different organs or
tissues for further metabolism. Under normal physiolo-
gical conditions, liver plays an important role to regulate
lipid and lipoprotein metabolisms. Liver not only
synthesizes and secretes endogenous lipoprotein, synth-
esis of key enzyme for the LDL metabolism, i.e., lecithin
cholesterol acyltransferase (LCAT), hepatic lipase and
apolipoproteins, but also regulates catabolism of various
plasma lipoproteins via hepatic cellular surface lipopro-
tein receptors, which may maintain relative equilibrium
of plasma lipids and lipoproteins in vivo [9,10]. These
processes could be interfered or impaired when hepatic
cellular damage, which leads to an alteration of plasma
Table 1 Characterization of patients and controls
Patients Control
Cases 30 30
Ages (Means ± SD) 41.7 ± 17.3 46.0 ± 13.6
Sex (male/female) 21/9 16/14
Hospitalization (days) 24.6 ± 15.3 Medical normal
ALT (IU/L) 1227.9 ± 690.7
Clinical diagnosis 25 cases of acute jaundice viral hepatitis, 5 cases of non-jaundice
Discharged Clinical cure
Infection 19 cases of HEV, 4 cases of HBV and seven cases of non-A non-E
Ultrasound examines 10 cases of hepatomegaly, 4 cases of hepatic cyst and 1 case hepatic hemangioma
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terol, triglycerides, apoAI, apoB and Lp(a) could be
changed and their plasma concentrations will be altered
correspondingly [11]. Therefore, examination of plasma
lipid and lipoprotein levels will be helpful to evaluate
the extent of the hepatic damage. It is well known that
plasma levels of cytokines, lipid peroxides and anti-oxi-
dant status could be changed under acute or chronic
hepatitis [12-14], which may also interfere the lipid
metabolism in vivo.
In the present results we demonstrated that plasma
levels of total cholesterol, HDL-C and apoAI were sig-
nificantly lower in the patients at the acute phase of
hepatitis than those in normal subjects, whereas plasma
levels of triglycerides and LDL-C were obviously higher
in the patients than in normal subjects. And patients’
plasma levels of total cholesterol, LDL-C, HDL-C and
apoAI were lower at the active phase of the diseases
than at the recovering phase, which indicating that
acute liver damage could significant influence lipid
metabolism in vivo. It is well known that severe acute
hepatitis is an serious acute inflammatory process that
leads to a hepatic cellular necrosis [15]. It has been
reported when acute hepatitis occurred, liver function
could be severely damaged, which could significantly
inhibit hepatic apoAI synthesis [16]. Serum levels of
apoAI, apoAII and total cholesterol were negatively cor-
related to serious of liver damage [17-19]. According to
our results and together with the literatures [20,21]
apoAI and HDL-C could be considered as the best indi-
cator to evaluate accurately the liver damage. The com-
bination of plasma levels of apoAI and HDL-C together
with prothrombin activity and serum levels of bilirubin
and transaminase could be a best index for evaluating
the prognosis of acute hepatitis.
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